Vytrus Biotech, a specialist in biotechnological active cosmetic ingredients from plant stem cells, closed the first half of 2026 with sales of 6 million euros, 37% more than in the same period of the previous year. This is reflected in the company's audited results, whose turnover for the last twelve months already amounts to 10 million euros.
The growth in revenues, coupled with an 11% increase in operating costs, has had a direct effect on profitability. EBITDA reached 3.51 million euros (68% more than in the first half of 2025) and its margin rose from 47.6% to 58.4%. Net profit, for its part, rose 79% to 2.58 million euros.
Europe and Latin America lead sales
By markets, the European Union, including Spain, led the advance with a growth of 49%. Spain, France and Italy maintained a good pace, and the company adds new projects in these countries and in others in southern and eastern Europe. Latin America was the most dynamic region, with 83% more sales thanks to Brazil, Mexico and Colombia. In Asia-Pacific, the increase was 24%, driven by India, Australia and Thailand. The rest of the markets grew by 54%, with the United Kingdom as the protagonist.
The negative note comes from the United States, where sales fell by 14% in a context of slowdown during the first months of the year. Vytrus expects this market to recover towards the end of 2026. In total, the company markets its products in 52 countries.
Well ageing, sensitive skin and sun protection, the strongest categories
By application areas, ingredients for well ageing, sensitive skin care and sun protection registered the best evolution of the semester. In terms of innovation, Vytrus has launched two new products, Toleroxyl and Ignilyte, with which it adds 24 ingredients to the market in 2026.